Camptosar®
Irinotecan is a topoisomerase I inhibitor used for the treatment of metastatic colorectal cancer. It prevents DNA religation during replication, inducing strand breaks.
| Dosage Form | IV Injectable (Solution) |
| Strength | 20 mg/mL; 40 mg, 100 mg, 300 mg vials |
| Storage | Store at 15–30°C. Protect from light. |
| Category | Oncology |
| Availability | Available for Transfer |
Metastatic colorectal cancer (first-line with 5-FU/leucovorin, or after failure of 5-FU-based therapy).
Binds to topoisomerase I-DNA complex and prevents religation of single-strand breaks. The resulting double-strand DNA damage leads to apoptosis.
Each Burrard Pharmaceuticals technology transfer package for Irinotecan includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.